Anti-MYO3A monoclonal antibody

Pre-made anti-MYO3A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYO3A/MYO3A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2616-Ab-1/ GM-Tg-hg-IP2616-Ab-2Anti-Human MYO3A monoclonal antibodyHuman
GM-Tg-rg-IP2616-Ab-1/ GM-Tg-rg-IP2616-Ab-2Anti-Rat MYO3A monoclonal antibodyRat
GM-Tg-mg-IP2616-Ab-1/ GM-Tg-mg-IP2616-Ab-2Anti-Mouse MYO3A monoclonal antibodyMouse
GM-Tg-cynog-IP2616-Ab-1/ GM-Tg-cynog-IP2616-Ab-2Anti-Cynomolgus/ Rhesus macaque MYO3A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2616-Ab-1/ GM-Tg-felg-IP2616-Ab-2Anti-Feline MYO3A monoclonal antibodyFeline
GM-Tg-cang-IP2616-Ab-1/ GM-Tg-cang-IP2616-Ab-2Anti-Canine MYO3A monoclonal antibodyCanine
GM-Tg-bovg-IP2616-Ab-1/ GM-Tg-bovg-IP2616-Ab-2Anti-Bovine MYO3A monoclonal antibodyBovine
GM-Tg-equg-IP2616-Ab-1/ GM-Tg-equg-IP2616-Ab-2Anti-Equine MYO3A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2616-Ab-1/ GM-Tg-hg-IP2616-Ab-2; GM-Tg-rg-IP2616-Ab-1/ GM-Tg-rg-IP2616-Ab-2;
GM-Tg-mg-IP2616-Ab-1/ GM-Tg-mg-IP2616-Ab-2; GM-Tg-cynog-IP2616-Ab-1/ GM-Tg-cynog-IP2616-Ab-2;
GM-Tg-felg-IP2616-Ab-1/ GM-Tg-felg-IP2616-Ab-2; GM-Tg-cang-IP2616-Ab-1/ GM-Tg-cang-IP2616-Ab-2;
GM-Tg-bovg-IP2616-Ab-1/ GM-Tg-bovg-IP2616-Ab-2; GM-Tg-equg-IP2616-Ab-1/ GM-Tg-equg-IP2616-Ab-2
Products NameAnti-MYO3A monoclonal antibody
Formatmab
Target NameMYO3A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYO3A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2616-Ag-1Recombinant multi-species MYO3A/ DFNB30 protein


    Target information

    Target IDGM-IP2616
    Target NameMYO3A
    Gene ID53904,667663,498806,707165,487106,101086983,535824,100055461
    Gene Symbol and Synonyms9030416P08Rik,DFNB30,MYO3A
    Uniprot AccessionQ8NEV4
    Uniprot Entry NameMYO3A_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000095777
    Target ClassificationKinase

    The target: MYO3A, gene name: MYO3A, also named as DFNB30. The protein encoded by this gene belongs to the myosin superfamily. Myosins are actin-dependent motor proteins and are categorized into conventional myosins (class II) and unconventional myosins (classes I and III through XV) based on their variable C-terminal cargo-binding domains. Class III myosins, such as this one, have a kinase domain N-terminal to the conserved N-terminal motor domains and are expressed in photoreceptors. The protein encoded by this gene plays an important role in hearing in humans. Three different recessive, loss of function mutations in the encoded protein have been shown to cause nonsyndromic progressive hearing loss. Expression of this gene is highly restricted, with the strongest expression in retina and cochlea. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.